Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013


March 18, 2013
534 Pages - SKU: GMD4999230
License type:


Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD).
  • A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Additional Information


Report Excerpt

Coverage

The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible. Changes the industry taxonomy are built on the basis of extensive research of company, association and competitor sources.Company coverage is based on three key factors: market capitalization, revenues and media attention/innovation/ market potential.An exhaustive search of 56 member exchanges is conducted and companies are prioritized on the basis of their market capitalization.The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage.Companies which are making the news, or which are of particular interest due to their innovative approach are prioritized.Global Markets Direct aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis.The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).

Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market.The secondary research sources that are typically referred to include, but are not limited to:Company websites, annual reports, financial reports, broker reports, investor presentations and SEC FilingsIndustry trade journals and other literatureInternal and external proprietary databasesNational government documents, statistical databases and market reportsNews articles, press releases and web-casts specific to the companies operating in the market.

More Respiratory/Pulmonary reports by Global Markets Direct

Pulmonary Tuberculosis – Pipeline Review, H1 2013 by Global Markets Direct
Pulmonary Tuberculosis – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Pulmonary Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This ...
Pulmonary Arterial Hypertension – Pipeline Review, H1 2013 by Global Markets Direct
Pulmonary Arterial Hypertension – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic ...
Cystic Fibrosis – Pipeline Review, H1 2013 by Global Markets Direct
Cystic Fibrosis – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Cystic Fibrosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This ...
Lung Cancer – Pipeline Review, H1 2013 by Global Markets Direct
Lung Cancer – Pipeline Review, H1 2013SummaryGlobal Markets Direct’s, 'Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This ...
See all reports like this >>